Prevalence of aminoglycoside-induced hearing loss in drug-resistant tuberculosis patients: A systematic review

Lauren K. Dillard*, Ricardo X. Martinez, Lucero Lopez Perez, Amanda M. Fullerton, Shelly Chadha, Catherine M. McMahon

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

1 Citation (Scopus)
3 Downloads (Pure)

Abstract

Objectives estimate the prevalence of ototoxic hearing loss in drug-resistant tuberculosis (DR-TB) patients treated with aminoglycoside antibiotics via a systematic review and meta-analysis. Estimate the annual preventable cases of hearing loss in DR-TB patients and leverage findings to discuss primary, secondary and tertiary prevention.

Methods studies published between 2005 and 2018 that reported prevalence of post-treatment hearing loss in DR-TB patients were included. We performed a random effects meta-analysis to determine pooled prevalence of ototoxic hearing loss overall and by medication type. Preventable hearing loss cases were estimated using World Health Organization (WHO) data on DR-TB treatment and prevalence determined by the meta-analysis.

Results eighteen studies from 10 countries were included. Pooled prevalence of ototoxic hearing loss and the corresponding 95% confidence interval (CI) was 40.62% CI [32.77– 66.61%] for all drugs (kanamycin: 49.65% CI [32.77– 66.61%], amikacin: 38.93% CI [26.44–53.07%], capreomycin: 10.21% CI [4.33–22.21%]). Non-use of aminoglycosides may result in prevention of approximately 50,000 hearing loss cases annually.

Conclusions aminoglycoside use results in high prevalence of ototoxic hearing loss. Widespread prevention of hearing loss can be achieved by following updated WHO guidelines for DR-TB treatment. When hearing loss cannot be avoided, secondary and tertiary prevention should be prioritized.

Original languageEnglish
Pages (from-to)27-36
Number of pages10
JournalJournal of Infection
Volume83
Issue number1
DOIs
Publication statusPublished - 1 Jul 2021

Bibliographical note

Copyright © 2021 The Authors. Published by Elsevier Ltd on behalf of The British Infection Association. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

Fingerprint

Dive into the research topics of 'Prevalence of aminoglycoside-induced hearing loss in drug-resistant tuberculosis patients: A systematic review'. Together they form a unique fingerprint.

Cite this